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Significance {#sec1}
============

**USARC is not a specific tumor entity but rather a "wastepaper basket" grouping of sarcomas that cannot be classified. There are limited therapeutic options for patients and the biology underlying USARC tumorigenesis remains poorly understood. We show that a genomic classification for USARC is clinically and biologically relevant. Deconvolution of the complex copy number and rearrangement landscapes highlight USARC as an exemplar model to study chromothripsis, early haploidy, and WGD events in cancer. We also show that these tumorigenic pathways are active to different degrees in other sarcoma subtypes from The Cancer Genome Atlas, shedding light on pan-sarcoma mechanisms of tumorigenesis.**

Introduction {#sec2}
============

Undifferentiated sarcomas (USARCs) of adults are soft tissue tumors that are among the most karyotypically complex of all cancers ([@bib52]). These tumors were previously known as malignant fibrous histiocytomas but historically have had multiple designations based on advances in diagnostic criteria ([@bib17]). They are diagnosed by exclusion of other sarcoma entities and likely represent a final common morphological endpoint of a variety of sarcomas and, possibly, other tumors ([@bib18]). Prognosis for these patients is poor, with a median survival for those with advanced, metastatic disease of approximately 12 months ([@bib48]). The benefit of systemic therapy, particularly in the adjuvant setting is controversial ([@bib35]). A lack of objective diagnostic criteria has led to a dearth of studies interrogating genomic complexity in these tumors at base pair resolution. The ability to probe this complexity is important because genomic instability is a key catalyst in cancer evolution, fuels tumor heterogeneity, and is relevant therapeutically ([@bib9]). The karyotypic complexity inherent in USARCs also suggests that interrogating and distilling structural aberrations in these tumors may yield large returns in our understanding of the disease.

Recent work from The Cancer Gene Atlas (TCGA) has characterized the cancer driver gene landscape of a number of soft tissue sarcoma types, including 44 undifferentiated pleomorphic sarcomas (henceforth TCGA.USARC) using a multi-omic approach ([@bib52]). Here, we sought to extend that work through whole genome sequencing (WGS), resulting in insights into USARC biology and evolution and potential avenues for treatment.

Results {#sec3}
=======

A collection of 76 tumor samples diagnosed using standard of care were selected for investigation, based on availability of adequate nucleic acid, and were required to be radio- and chemotherapy naive in order to ensure high-quality, tumor-rich specimens and to avoid confounding by prior treatment. Eight cases were reclassified as other sarcoma entities through pathological review or genomic characterization and thus excluded ([STAR Methods](#sec6){ref-type="sec"} and [Figure 1](#fig1){ref-type="fig"}A). Tumors were classified into morphological variants (pleomorphic, spindle, epithelioid, or mixed) according to the most recent guidelines ([@bib55]) for further analysis ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Molecular Classification of USARCs(A) Alluvial diagram showing tumor diagnosis reclassification following expert pathological review. UPS, undifferentiated pleomorphic sarcoma; USARC, undifferentiated sarcoma; UCS, unclassified sarcoma; SCS, spindle cell sarcoma; S, spindle; P, pleomorphic; E, epithelioid; MPNST, malignant peripheral nerve sheath tumor; DDLPS, dedifferentiated liposarcoma; M-SFT, malignant solitary fibrous tumor; Ped. SCS, pediatric spindle cell sarcoma. Numbers indicate the number of samples for each subtype.(B) H&E staining of four representative USARC subtypes. Scale bars, 250 μm.(C) Mean methylation of probes categorized by genomic position (left) or position relative to CpG islands (right), in USARC samples (orange) and normal adjacent tissue (green); ^∗^q \< 0.05, ^∗∗^q \< 0.01, ^∗∗∗^q \< 0.001. Boxes show lower quartile, median and upper quartile; lines denote furthest point within 1.5× the interquartile range away from the box; points denote data further than 1.5× the interquartile range away from the box.(D) Principal-component analysis of tumor (orange) and normal (green) samples for both methylation array data (left) and RNA sequencing data (right) as well as shared hierarchical clustering of RNA and methylation data (center).(E) Scatterplot of rearrangement burden (x axis) against SNV/indel burden (y axis) of USARC samples from WGS. Samples were categorized into three groups: mutation high, rearrangement low (mutHi-rearrLo, purple), mutation low, rearrangement high (mutLo-rearrHi, red), and mutation low, rearrangement low (mutLo-rearrLo, blue). Decision boundary is shown as a dashed line. Filled circles are individual data points, ovals 50% probability intervals.(F) Number of samples that have ≥1 rearrangement in genomic windows of 1 Mb (top), number of samples that have chromothriptic regions overlapping genomic windows of 1 Mb (middle), and rearrangement partners of rearrangements within regions that are significantly enriched (bottom). Regions with significant enrichment (q \< 0.2) are labeled.See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

USARCs Are Characterized by Relative Global Hypomethylation Compared with Normal Muscle {#sec3.1}
---------------------------------------------------------------------------------------

Biologically relevant subgroups of mesenchymal tumors have recently been identified through DNA methylation profiling ([@bib46]). These molecular classification schemes hold great promise for sarcoma clinical diagnostics and add value to the traditional histological classification for prognostication. To determine if molecularly defined subgroups could be identified in USARCs, we performed genome-wide methylation profiling (EPIC array) and gene expression analysis (RNA sequencing, [Table S1](#mmc2){ref-type="supplementary-material"}) for all tumor samples for which sufficient high-quality nucleic acid was available. Compared with adjacent normal tissues (skeletal muscle) USARC methylomes showed relative hypomethylation on a genome-wide scale with the majority of the signal confined to intergenic regions of the genome and in "open sea" regions rather than in promoter regions or CpG islands ([Figure 1](#fig1){ref-type="fig"}C), and this result was reproduced in the TCGA.USARC dataset ([Figure S1](#mmc1){ref-type="supplementary-material"}A).

Principal-component analysis of both the methylation and gene expression data revealed strong separation between tumor and normal samples; however, it failed to delineate any clear subgroups within USARCs ([Figure 1](#fig1){ref-type="fig"}D), and, similarly TCGA.USARC are heterogeneous and do not represent a distinct sarcoma subtype at the DNA methylation level ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Using unsupervised hierarchical clustering we also found that there was poor concordance between the methylation and the gene expression sample clusters at a global level ([Figure 1](#fig1){ref-type="fig"}D), reflecting the finding that global changes in methylation were more prominent in non-genic regions. In addition, there were no associations with histological subtype.

Both Mutational and Rearrangement Burden Are Characteristics of Genomic Complexity in USARCs {#sec3.2}
--------------------------------------------------------------------------------------------

We then analyzed 52 of the USARC samples using WGS, which were sequenced to an average depth of 70× along with DNA from blood from the same patients sequenced to 30× depth ([Table S1](#mmc2){ref-type="supplementary-material"}). Somatic variant calling was performed using a validated suite of software and bespoke post-processing filters. Per sample, the median number of single nucleotide variants (SNVs) was 4,741 (range: 2,164--32,108) ([Table S1](#mmc2){ref-type="supplementary-material"}), of indels was 449 (range: 180--20,073) ([Table S1](#mmc2){ref-type="supplementary-material"}), and of rearrangements was 166 (range: 23--514) ([Table S1](#mmc2){ref-type="supplementary-material"}). A further extension cohort of 16 samples of USARCs ([Table S1](#mmc2){ref-type="supplementary-material"}) were sequenced to a mean target depth of 403× on a cancer gene exome panel covering 3 Mb of the genome, including intronic coverage of *TP53*, *RB1*, *ATRX*, and *CDKN2A*.

USARCs present a relatively low median SNV/indel mutational burden and a high median number of rearrangements and resulting copy-number alterations ([Figure S1](#mmc1){ref-type="supplementary-material"}C). However, a subgroup presented with high SNV/indel and low rearrangement burdens. We thus classified USARCs into three molecular subgroups: mutation high---rearrangement low (mutHi-rearrLo); mutation low----rearrangement high (mutLo-rearrHi); and mutation low---rearrangement low (mutLo-rearrLo; [Figure 1](#fig1){ref-type="fig"}E, [Table S1](#mmc2){ref-type="supplementary-material"}). Of the 45 tumors demonstrating 15,000 or fewer SNV/indel mutations across the genome, 33 patients harbored 100 or more rearrangements per tumor (mutLo-rearrHi group). In contrast, 7 tumors demonstrated a hypermutator phenotype with a minimum of 15,000 SNV/indel mutations per tumor (\>5 mutations per Mb; median 28,370), all of which had a relatively low rearrangement burden (median 68) (mutHi-rearrLo group). The third molecular subgroup consisted of 12 tumors with modest rearrangement and mutational burdens in comparison with the others (mutLo-rearrLo). Extension samples were classified as mutation high (tMutHi) or mutation low (tMutLo).

Mismatch Repair Deficiency in the Muthi-rearrLo USARC Subgroup {#sec3.3}
--------------------------------------------------------------

The finding that ∼13% (n = 7) of USARC samples had an elevated mutational burden prompted further investigation. We found somatic driver SNVs within *MSH2* in two cases (PD26873a and PD26876a), both with somatic copy-number loss of the wild-type allele ([Table S1](#mmc2){ref-type="supplementary-material"}). However, we also observed aberrations in *MSH2*, including promoter methylation (PD26868a; [Figure S2](#mmc1){ref-type="supplementary-material"}A) and a predicted disruptive translocation on the forward strand in intron two associated with loss of heterozygosity (LOH) (PD26866a [Figure S2](#mmc1){ref-type="supplementary-material"}B). A fifth patient (PD31196a) was found to have a pathogenic germline mutation in *MSH6* (p.V878A) with somatic loss of the wild-type allele in the tumor. All five of these tumors exhibited mutational signatures of mismatch repair (MMR) deficiency (signatures 6, 15, 26, and 40, [Figure S2](#mmc1){ref-type="supplementary-material"}C) and protein loss of one or both of MSH2 and MSH6 ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

Sample PD31203a showed a mutational signature (signature 30) that strongly matched the base excision repair *NTHL1* deficiency pattern ([Figure S2](#mmc1){ref-type="supplementary-material"}E), previously only seen in a breast cancer ([@bib41]) and an osteosarcoma ([@bib5]). A rare pathogenic germline heterozygous nonsense mutation of *NTHL1* (pQ90^∗^) with somatic loss of the wild-type allele was confirmed in this patient. Finally, PD26882a showed more than 28,000 mutations with strong activity of signature 1 with almost pure C \> T transitions in a CpG context, likely caused by spontaneous deamination of methylated cytosines ([@bib2]). Such a strong activity of signature 1 and without evidence of MMR deficiency raised the possibility of failure of repair of the deaminated cytosines. This was confirmed by the discovery of biallelic inactivation of the DNA glycosylase gene *MBD4* ([Figure S2](#mmc1){ref-type="supplementary-material"}F). *MBD4* prevents mutability at CpG sites and is a binding partner of the MMR protein MLH1 ([@bib6]). To the best of our knowledge, this is the first description of defective MBD4-associated DNA repair in sarcomas.

*TP53*, *RB1*, *CDKN2A*, *ATRX*, and 5p15.33 (*TERT*) Rearrangements Are Recurrent {#sec3.4}
----------------------------------------------------------------------------------

Leveraging the higher resolution of WGS, we called putative structural variants and scrutinized these in order to identify potential cancer driver gene events.

As fusion genes are characteristic of many sarcoma subtypes, we first looked for structural variants causing gene fusions. Results of these analyses suggest that oncogenic chimeric fusions are rare events in the pathogenesis of USARCs ([Table S1](#mmc2){ref-type="supplementary-material"}). Conversely, for identification of recessive mechanisms, we sought truncating rearrangements and overlapped these regions with known recessive cancer genes ([@bib19]). We identified 51 recurrently rearranged genes, 9 of which are known tumor suppressor genes ([Table S1](#mmc2){ref-type="supplementary-material"}). In particular, recurrent disruptive rearrangements were identified in *TP53*, *RB1*, and *ATRX.* Using a bespoke tool for chromothripsis identification we noted that, while the *TP53* region is highly rearranged, only 1/23 rearranged samples have been identified as chromothriptic in that region compared with 5/9 samples with *ATRX* rearrangements (Fisher\'s exact test, p \< 0.01, odds ratio = 23.5, [Figure S2](#mmc1){ref-type="supplementary-material"}G). These data suggest that chromothripsis is an infrequent mechanism of *TP53* disruption in USARCs and that inactivation of tumor suppressor genes rather than activation of oncogenes is the sine qua non of the USARC rearrangement phenotype. A gene-agnostic method was then used to widen our search for recurrently rearranged regions. Three genomic windows incorporating 5p15.33, 17p13.1, and 17p11.2 were identified as harboring significant rearrangements across samples (false discovery rate \[FDR\]: q \< 0.2) ([Figure 1](#fig1){ref-type="fig"}F). The 17p13.1 region harbors *TP53*.

Two other recurrently rearranged regions containing canonical cancer driver genes *RB1* and *CDKN2A* were identified by this method but were not significant following multiple testing (FDR: q ≥ 0.2).

There was an enrichment of diverse rearrangements on the boundaries of the *TERT* gene (5p15.33), which encodes the catalytic subunit of telomerase ([Figure S3](#mmc1){ref-type="supplementary-material"}A). One mechanism of activating *TERT* is through rearrangements that colocalize *TERT* with distant enhancer regions, so-called "enhancer hijacking" ([@bib42]). By overlapping the genomic positions of the boundaries of structural breakpoints with the dbSUPER ([@bib29]) database of 91 human and mouse tissue types, we identified that of the 13 rearrangements (8 translocations, 4 inversions, and 1 tandem-duplication; 7 downstream, 5 upstream, and 1 within TERT) within 100 kb of *TERT*, 8 rearrangements have a partner region that directly overlaps or is within 500 kb of a super enhancer in all tissues or muscle tissues only. Furthermore, in those samples with such rearrangements we found that the expression of *TERT* was significantly increased ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These data strongly suggest that *TERT* enhancer capture is being tagged by rearrangements in the region. Because *TERT* is known to be dysregulated through multiple mechanisms, this finding prompted a search for other potential mechanisms of *TERT* activation. There were no predicted *TERT* fusion events. However, two cases (PD26857a and PD31187a) demonstrated hypermethylation of the repressive element within the *TERT* promoter locus ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We also found evidence for increased telomere length (tumor:normal ratio) in the majority of samples and disruption in either *ATRX* or *DAXX* or in the *TERT* promoter ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E).

To determine the significance of rearrangements in the 17p11.2 region we correlated gene expression for all genes in the cytoband with rearrangement status. This revealed two genes with significantly altered expression namely *GID4* and *RASD1* ([Figure S3](#mmc1){ref-type="supplementary-material"}F); *GID4* encodes a coactivator of RNA polymerase II and has increased expression in the rearranged samples (p = 2.0 × 10^−3^, q = 5.6 × 10^−3^). *RASD1*, encoding a member of the RAS family, has a significantly reduced expression in rearranged samples (p = 5.9 × 10^−4^, q = 2.6 × 10^−3^). In line with this observation, it has previously been proposed that *RASD1* is a tumor suppressor gene in some cancer types ([@bib20]).

Integration of Driver Mutations, Rearrangements, and Copy-Number Variants {#sec3.5}
-------------------------------------------------------------------------

Using a statistical model for mutational driver analysis we found four recurrent driver genes from WGS, all of which are known cancer genes (*TP53*, *RB1*, *PTEN*, and *ATRX*, q \< 0.2; [Table S2](#mmc3){ref-type="supplementary-material"}). In addition, using this method *MEN1* was identified as somatically mutated in four samples (6%). *MEN1* mutations have not previously been reported in sarcomas and have been described only occasionally in benign smooth muscle tumors and rarely in lipomas ([@bib19]). These mutations included two frameshift deletions (PD26863a p.F370Sfs^∗^65; PD26873a p.R521Gfs^∗^43), a nonsense mutation (PD31196a p.R532^∗^) and an in-frame deletion (PD26877a p.G168_L173delinsV). Copy-number calling ([Table S2](#mmc3){ref-type="supplementary-material"}) followed by recurrent copy-number analysis revealed significant recurrent altered regions of the USARC genome including amplification of the known sarcoma driver oncogenes *JUN* and *RICTOR*, and deletion of cancer driver genes such as *TP53*, *RB1*, *CDKN2A*, *CBFA2T3*, *STK11*, *TCF3*, and *CYLD* (GISTIC, q \< 0.1; [Figure 2](#fig2){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}).Figure 2Integration of Driver Events in USARCs(A) Heatmap showing significant recurrently amplified or deleted regions (GISTIC q \< 0.1). Known cancer driver genes in amplified regions are labeled in blue and those in deleted regions are labeled in red. Lengths of significant regions (Mb) are indicated above the heatmap, with --log2(q values) below.(B) SNV and indel mutational burden barplot (top) and copy-number alterations, SNVs, small indels, structural variants and promoter methylation alterations in known cancer genes (middle), with clinical and genetic covariates (bottom). Red text indicates driver genes identified by dNdSCV (q \< 0.2). stab, genome stability; CC, cell cycle; tel, telomere maintenance; mTOR, mTOR signaling pathway; men, MENIN pathway; repair, DNA repair. Samples are ordered by sequencing platform, burden group, and mutational status.See also [Table S2](#mmc3){ref-type="supplementary-material"}.

We then integrated mutational and structural variants into a comprehensive USARC driver mutation landscape ([Figure 2](#fig2){ref-type="fig"}B), noting from the WGS data that up to 50% of driver events in *TP53*, *RB1*, and *ATRX* would have been missed if only exome data were available for the cohort. Furthermore, from a potential therapeutic standpoint, mutational profiling and manual curation of driver variants revealed that 33% (n = 17) of tumors harbored mutations in genes encoding proteins upstream of mammalian target of rapamycin (mTOR) in the signaling cascade. These included truncating events in *PTEN* (n = 10), *TSC1* (n = 2), and *TSC2* (n = 2), as well as a hotspot mutation in *PIK3CA* (p.H1047R).

Hypermutation Fuels Subclonal Mutations in Cancer Genes {#sec3.6}
-------------------------------------------------------

Data showing that sarcomas have relatively modest mutational burdens compared with other cancer types ([@bib10]) prompted an investigation to determine whether high-depth sequencing might reveal a wider spectrum of cancer driver genes than identified by our 70× depth for WGS. We therefore sequenced our 7 hypermutated samples and an extension cohort of 16 new USARC samples ([Table S3](#mmc4){ref-type="supplementary-material"}) to a mean target depth of 403× on a cancer driver gene panel. Analysis of the hypermutated samples revealed that up to 18% of variants had not been reported in the WGS ([Figure 3](#fig3){ref-type="fig"}A) and were dominated by subclonal mutations ([Figure 3](#fig3){ref-type="fig"}B). In the extension cohort, the spectrum of driver genes mirrored that of the WGS data ([Figure 2](#fig2){ref-type="fig"}B), which is also reflected in the TCGA.USARC samples. We also found three hypermutated samples (∼19%) in the extension cohort, one of which harbored a nonsense mutation of *PALB2* (pE331^∗^). Two samples lacked an identifiable causative mutation in either the somatic or germline genome using the targeted approach.Figure 3Implications of Increased Tumor Mutational Burden(A) Venn diagram of predicted pathogenic variants from mutHi samples identified from targeted sequencing (left) and identified from WGS in regions overlapping the design of the targeted baitset (right).(B) Variant allele frequency (VAF) of all variants (left) or variants only observed by targeted sequencing (right).(C) Overall survival of patients stratified by mutational burden and with a univariate Kaplan-Meier model.(D) Multivariate accelerated failure time model for progression-free survival with size of tumor, resection status, and burden group as covariates.(E) Gene set enrichment analysis for interferon gamma response (green) and antigen presentation (purple) pathways using both DNA methylation (top) and gene expression (bottom) data comparing the mutHi-rearrLo group against all others. See also [Table S3](#mmc4){ref-type="supplementary-material"}.

Utility of a Genomic Classification for USARCs {#sec3.7}
----------------------------------------------

The histological classification of USARCs has a chequered history and is based on exclusion of other sarcoma entities ([@bib16]). There is a pressing need to address the inconsistencies of the current classification because the morphologically heterogeneous nature of USARCs and its genomic complexity have resulted in a deficiency in identification of biomarkers that could inform risk stratification and clinical management strategies. To test whether classifying USARCs by mutational burden might have prognostic significance we conducted a survival analysis using both a univariate analysis ([Figure 3](#fig3){ref-type="fig"}C) and a robust parametric statistical model using multivariate clinical and molecular data including the mutational subgroups ([Figure 3](#fig3){ref-type="fig"}D). This revealed that the mutHi group showed significantly better progression-free and metastasis-free survival ([Table S3](#mmc4){ref-type="supplementary-material"}) compared with mutLo groups. As expected, metastasis was found to have a significantly detrimental effect on overall survival ([Table S3](#mmc4){ref-type="supplementary-material"}). There was no significant survival effect associated with any of the most recurrently mutated genes after accounting for clinical confounders. Furthermore, pathway analysis revealed significant enrichment for immune-related pathways in mutHi compared with other samples, suggesting an altered immune response in those samples with a high tumor mutational burden ([Figure 3](#fig3){ref-type="fig"}E). The same trend was observed in TCGA hypermutators, although the sample size (n = 3) was not sufficient for a significant result (data not shown).

Rearrangement Signatures Reveal Distinct Patterns of Structural Variation {#sec3.8}
-------------------------------------------------------------------------

The rearrHi and rearrLo molecular subgroups highlight the diversity in rearrangement burden in USARCs, and, indeed, the nature of structural rearrangements in USARCs is also varied ([Figure 4](#fig4){ref-type="fig"}A). We sought to investigate the rearrangement processes underpinning this landscape. To this end we extracted recurring rearrangement signatures ([@bib41]) based on the nature, size distribution, and local clustering of structural variants. Using a non-negative matrix factorization mathematical framework, we identified five predominant signatures (USARC.RS1-USARC.RS5; [Figure 4](#fig4){ref-type="fig"}B; [Table S4](#mmc5){ref-type="supplementary-material"}). Interestingly USARC.RS1 and USARC.RS5 were strongly dominated by translocations and showed a comparative dearth of other rearrangement classes. These signatures are differentiated from each other by the presence of proximity clustering of the breakpoint regions, suggestive of alternate rearrangement mechanisms ([@bib24]). The remaining signatures (USARC.RS2 to USARC.RS4) showed a more varied pattern of rearrangement classes.Figure 4Rearrangement Signatures(A) Rearrangement diversity and counts in the USARC cohort, classified by rearrangement size and rearrangement class.(B) Five rearrangement signatures identified by non-negative matrix factorization (NMF); USARC.RS1, clustered translocations (tloc, purple); USARC.RS2, small unclustered tandem duplications (TD, green), inversions (inv, red), and deletions (del, blue); USARC.RS3, large unclustered TDs, invs, and dels; USARC.RS4, large clustered TDs, invs, and dels; USARC.RS5, unclustered tlocs. x axis, strength of each rearrangement class in each signature.(C) Contribution of activities of each signature per sample (left) and cosine similarities between published breast cancer rearrangement signatures (BRCA.RS1-6) and USARC rearrangement signatures (right). See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc5){ref-type="supplementary-material"}.

By contrasting these five sarcoma signatures with a published WGS dataset of breast cancer ([@bib41]), we found that USARC.RS1, USARC.RS4, and USARC.RS5 have previously been identified, suggesting common mechanisms driving structural variation between these diverse cancer types ([Figure 4](#fig4){ref-type="fig"}C). Unsurprisingly, the activities of the two signatures of clustered rearrangements, USARC.RS1 (clustered translocations) and USARC.RS4 (clustered tandem duplications, inversions and deletions), were associated with the number of chromothriptic chromosomes (linear regression, p = 3.3 × 10^−5^, q = 8.7 × 10^−4^; p = 1.1 × 10^−2^, q = 8.7 × 10^−2^, respectively; [Figure S4](#mmc1){ref-type="supplementary-material"}). USARC.RS2 signature activity was seen in 52% of samples (median exposure = 7%, interquartile range \[IQR\] = 0%--13%) and is characterized by unclustered co-occurring megabase scale tandem duplications, deletions, and inversions. USARC.RS3, which was seen in 92% of samples (median exposure = 30%, IQR = 23%--45%), has a similar overall pattern to USARC.RS2, but shows a different segment size distribution favoring longer lengths, possibly indicating divergent mechanisms of generation. This intriguing set of results called for a deeper understanding of the impact of extensive and complex structural variation on the copy-number profiles of USARCs.

The Genomic Complexity of USARCs Is Unraveled Using Copy-Number Signatures {#sec3.9}
--------------------------------------------------------------------------

Accurate inference of the nature and role of copy-number aberrations in most samples was hindered by substantial complexity, demonstrated by multiple large and small chromosomal gains and losses across the genome and compounded by whole genome duplication (WGD) events. We adopted a pragmatic approach that deconvoluted complex copy-number profiles into various distinct operative copy-number processes and then compared these across samples to make inferences about their development and effects. Copy-number profiles were summarized into a metric by classifying copy-number segments according to size, LOH status, and total copy number. This framework identified seven copy-number signatures (CNS1-7; [Figures 5](#fig5){ref-type="fig"}A and 5B; [Table S5](#mmc6){ref-type="supplementary-material"}). CNS1 is a signature indicative of amplified LOH, which correlates with two or more WGD events (asymptotic Wilcoxon-Mann-Whitney test, *Z* = −4.84, p = 4.5 × 10^−7^, q = 2.6 × 10^−7^; [Figure 5](#fig5){ref-type="fig"}C). CNS2 is a signature of duplicated LOH that may signify a single WGD. CNS3 is a signature of hypodiploid tumors (no evidence of WGD) with a large proportion of unaltered segments, and some small amplifications and large deletions. CNS4 is a signature of copy neutral LOH. CNS5 has features of amplification with retention of heterozygosity and neutral LOH segments. CNS6 is a complex copy-number signature comprising large heterozygous neutral and duplicated segments with smaller LOH segments of multiple copy-number states. CNS7 is the signature that is observed in the highest proportion of samples (67% of samples) and is a signature of a single WGD. These features of WGD with retention of heterozygosity and losses seen in CNS6 and CNS7 appear to fit a described model of tetraploidization followed by genomic losses, thereby generating an aneuploid cell state, particularly in a p53- and/or RB1-deficient background ([@bib12]).Figure 5Copy-Number Signatures(A) Seven copy-number signatures identified using NMF; amp, amplified (CN ≥ 1, orange); dup, duplicated (3 ≤ CN ≤ 4, purple); neut, neutral (CN, 2, green); del, deletion (CN ≤ 1, blue); homdel, homozygous deletion (CN, 0, gray); het, heterozygous. x axis, strength of each copy-number class in each signature.(B) Activities of copy-number signatures (CNS) per sample, with associated proportion of the genome that shows LOH, and molecular classification groups.(C) Density plot of CNS1 activity stratified by whether the sample has one or fewer genome doubling events (WGD\<2) or has two genome doubling events (WGD×2). Thickness of gray region indicates density. Small vertical lines, data points. Large vertical lines, median.(D) Density plot of CNS1 activity stratified by *TP53* mutation status.(E) Scatterplot of CNS5 activity against number of chromothriptic chromosomes. Gray line indicates linear fit.(F) Scatterplot of CNS5 activity against USARC.RS1 activity. Gray line indicates linear fit.(G) Diversity estimates of CNS in TCGA sarcoma subtypes and our USARC cohort.(H) CNS5 activity stratified by tumor type in TCGA.Boxes show lower quartile, median, and upper quartile; lines denote furthest point within 1.5× the interquartile range away from the box. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc6){ref-type="supplementary-material"}.

Furthermore, our earlier integrative mutational analysis revealed that 68% of tumors harbored a putative disruptive event in *TP53*, and that abrogation of *TP53* was significantly associated with activity of CNS1 (LOH with two or more WGDs) (Kruskal-Wallis test, p = 9.2 × 10^−4^, q = 1.3 × 10^−2^; [Figure 5](#fig5){ref-type="fig"}D). *PTEN* mutations are associated with an increased activity of the signature of copy neutral LOH, CNS4 (Kruskal-Wallis test, p = 3.9 × 10^−3^, q = 4.3 × 10^−2^), and activity of CNS4 is also correlated with tumor mutational burden (linear regression, p = 5.3 × 10^−3^, q = 5.1 × 10^−2^). The number of chromothriptic chromosomes in a sample is significantly correlated with activity of CNS5 (linear regression, p = 7.2 × 10^−7^, q = 2.6 × 10^−5^; [Figure 5](#fig5){ref-type="fig"}E) and samples that harbor chromothriptic chromosomes are enriched in the rearrHi group but are not associated with metastasis ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Activity of CNS5 across the cohort is also highly similar to the activity of the rearrangement signature of clustered translocations, USARC-RS1 (cosine similarity = 0.82; linear regression, p = 3.2 × 10^−8^, q = 5.8 × 10^−6^; [Figure 5](#fig5){ref-type="fig"}F). We then sought to determine the effects of these intriguing copy-number patterns on gene expression. We found a consistent and strong gene dose effect of the DNA copy number on RNA expression ([Figure S5](#mmc1){ref-type="supplementary-material"}C); however, there was no consistent pathway enrichment correlated with copy-number groups, compatible with the fact that most of the copy-number events are private events. Further, linear modeling of gene expression in genes of interest identified a significant relationship between gene expression and copy number in five genes (*TP53*, *RB1*, *CDKN2A*, *PTEN*, and *TERT*; q \< 0.05), but no significant association between promoter methylation and gene expression once copy number is accounted for (q \> 0.05).

USARCs Show Extreme Copy-Number Heterogeneity {#sec3.10}
---------------------------------------------

To explore the extent to which the copy-number signatures were operative in other samples, we compared our findings with a cohort of 320 sarcomas of multiple subtypes including samples from TCGA, the allele-specific copy-number states of which were extracted from WGS and high-resolution SNP arrays. Three signatures were identified in this validation cohort ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6D), all three of which were also identified in USARCs (CNS1, CNS3, and CNS7). CNS3, which is a signature of hypodiploid tumors, was highly operative in synovial sarcoma and a spectrum of low-grade sarcomas, both of which have low karyotypic complexity and rarely show WGD.

We then quantified the within-sample copy-number heterogeneity among different sarcoma types using a diversity index. This demonstrated that the lowest copy-number diversity is seen in synovial sarcoma, which is typically dominated by CNS3. The two USARC cohorts have the same degree of copy-number diversity, being the highest among various sarcoma types and is indistinguishable from the copy-number diversity seen in myxofibrosarcoma (MFS) ([Figure 5](#fig5){ref-type="fig"}G). This indicates that multiple processes generate copy-number alterations in USARCs, leading to a highly chaotic and varied copy-number landscape within each sample and across samples. Interestingly, dedifferentiated liposarcoma (DDLPS), a high-grade sarcoma that can show similar morphological heterogeneity and pleomorphism to USARCs showed a significantly lower CNS diversity (Mann-Whitney test; p = 0.003). This reduced diversity in DDLPS is reflected by a predominance of CNS5 in this tumor type ([Figure 5](#fig5){ref-type="fig"}H). Chromothripsis, particularly of chromosome 12, is a key driver event in DDLPS pathogenesis ([@bib21]), which is identified in these samples through the observation of CNS5. These findings illustrate that DDLPS samples have more similar characteristics to each other than USARC samples do.

Pseudohaploidization Is Recurrent in USARCs {#sec3.11}
-------------------------------------------

In view of the large proportion of our cohort of USARC samples bearing different spectra of LOH and the identification of copy-number signatures strongly defined by an LOH pattern, e.g., CNS4, we investigated this phenomenon in greater detail. We found that 14 tumors (27%) in our USARC cohort demonstrate widespread LOH (\>50% genome LOH) and that 3 tumors exhibit striking near-genome-scale haploidy (\>90% genome LOH). These data suggest that haploidization may be a common event in USARC evolution. To independently investigate this mechanism, we carried out ploidy analysis to estimate both DNA content and visualize nuclear morphology. This revealed diverse cell states with multiple cell fractions of increasing ploidy indicative of successive WGDs in samples ([Figure 6](#fig6){ref-type="fig"}A). One sample revealed an intact near-haploid subclone that constituted 9% of tumor cells, suggesting that the genome-duplicated clone had not completely swept through the tumor in this sample and might have been fueled by the near-haploid population ([Figure 6](#fig6){ref-type="fig"}B). Large-scale haploidy has previously been described using SNP arrays in low-grade chondrosarcoma ([@bib8]) and in other sarcoma subtypes ([@bib40]) of various grades.Figure 6LOH and Haploidization Are Frequent Events in USARCs(A) Histogram of DNA content, measured as integrated optical density (IOD) (x axis), for cell nuclei from PD26890. Proportion of genome LOH = 44%. 2c, median IOD of normal cell nuclei.(B) Histogram of DNA content for cell nuclei from PD26873. Proportion of genome LOH = 93%.(C) Proportion of samples within the USARC WGS cohort that are LOH (y axis) in sliding windows of the human genome of size 1 Mb each separated by 100 kb (x axis). Dashed line, boundary of regions with highly recurrent LOH (\>0.8) or retention of heterozygosity (\<0.2). Regions with retention of heterozygosity are highlighted with a horizontal black line. Regions with recurrent LOH are labeled with putative driver tumor suppressor genes in those regions.

Recurrent regions of LOH included the loci of *RB1* (chromosome 13q14.2) and *TP53* (chromosome 17p13.1) ([Figure 6](#fig6){ref-type="fig"}C), with 88% and 63% of mutational events co-occurring with LOH, respectively ([Figure 2](#fig2){ref-type="fig"}B), highlighting how the LOH background makes USARCs propitious to double-hits on tumor suppressors. Conversely, there were retained regions of heterozygosity on chromosomes 1, 2, 4, 5, 7, 9, 19, and 21 in \>80% of samples ([Figure 6](#fig6){ref-type="fig"}C). Proliferation rates determined by mitotic counts did not differ between samples with and without LOH and aberrant mitoses were prevalent in all samples (data not shown). Finally, we investigated the relationship between LOH and chromothripsis across our dataset and found negative associations between CNS5, the signature of chromothripsis, and both the proportion of genome that is LOH (linear regression, p = 2.1 × 10^−4^, q = 3.8 × 10^−3^), and the sum of all LOH-associated signatures, CNS1-4 (linear regression, p = 2.1 × 10^−7^, q = 2.0 × 10^−5^).

Timing of Polyploidization and Driver Mutations in Sarcomas {#sec3.12}
-----------------------------------------------------------

To better understand the contribution of polyploidization to the tumorigenesis of USARCs we used the copy-number data to interrogate patterns of WGD. A total of 89% of samples exhibited at least one WGD event, and 19% of samples showed at least two WGDs ([Figure 7](#fig7){ref-type="fig"}A). This contrasted remarkably with the average WGD occurrence of 37% across multiple cancer types ([@bib56]), indicating that WGD is an important tumorigenic event in USARCs. Mutational data were then integrated with the WGD analysis to infer both relative and real-time timing of WGD events. Categorizing samples by their most prevalent copy-number signature ([Figures 7](#fig7){ref-type="fig"}B--7D) revealed differential WGD timing in USARCs; groups of samples with potentially multiple WGDs, CNS5 and CNS1, have predominantly early first WGD, whereas CNS4 tumors have predominantly late WGD events, with the exception of two of the hypermutators in that group. The molecular timing of second WGDs, in cases where WGD was amenable to timing ([Table S6](#mmc1){ref-type="supplementary-material"}), showed that most occurred close to diagnosis, whereas the first WGD arose across a range of molecular times. The time between the first and second WGD is often in the order of decades, while the time between second WGD and diagnosis is considerably shorter. This analysis was extended to the sarcoma cohort of TCGA ([Figure 7](#fig7){ref-type="fig"}E), that showed the largest range of WGD times in USARCs, and confirmed early WGD in CNS5, drastically contrasting the late WGD in DDLPS of the same signature group.Figure 7Timing of Genome Duplication and Driver Mutations(A) The number of WGD determined by the mode of the major allele in a sample (mode 1, diploid, 0×WGD; mode 2, tetraploid, 1×WGD; mode \>2, octoploid, 2×WGD) matches inference from the spread of the samples in the proportion of LOH versus ploidy space.(B) Time of WGD (circles/squares, mean timing per sample. Square indicates more than 10,000 SNVs and circle is less than 10,000 SNVs; vertical colored bars, 95% confidence intervals on the mean values) in years before diagnosis, split by predominant copy-number signature in USARC cohort whole genomes.(C) Time of WGD in the sarcoma cohort of TCGA, split by tumor type.(D) Relative timing of driver mutations (colored circles) and WGD events (empty/gray circles) using the mutations as a molecular clock in USARC cohort whole genomes. Vertical bars, 95% confidence intervals. Samples split by predominant copy-number signature.(E) Relative timing of driver mutations and WGD events in the sarcoma cohort of TCGA. Samples split by predominant copy-number signature, and subdivided by tumor type. Vertical bars, 95% confidence intervals.Boxes are delimited by first and third quartiles; the thick segment shows the median; and whiskers extend to the last data points within 1.5 of the box length away from the box. See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S6](#mmc1){ref-type="supplementary-material"}.

Timing of driver mutations demonstrated that the vast majority of driver mutations occurred before the first WGD in USARCs ([Figure 7](#fig7){ref-type="fig"}D). Of interest in the USARC cohort are three samples with age of diagnosis \<40 years (within the 5% quantile of diagnostic age of USARCs and MFS; mean = 67.8 years), all of which have a late WGD. Indeed, there is a trend toward late WGD in patients with a younger age at diagnosis (linear regression, p = 0.066). Extending this analysis to the sarcoma cohort of TCGA ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}A--S7F) revealed an enrichment for a second WGD (CNS1) in USARC/MFS. WGD was predominantly late in CNS5 DDLPS, and predominantly early in CNS5 USARC, confirming the results in our cohort. Remarkably, in CNS1, which was associated with *TP53* LOH, the two *TP53* mutations amenable to timing in USARCs seemed to have occurred posterior to the first WGD but before the second WGD, suggesting that while the first WGD in these samples restored the diploid copy-number state, a further hit was necessary to reinstate *TP53* inactivation.

USARCs Are Heterogeneous Tumors with Evidence for Subclonal WGD {#sec3.13}
---------------------------------------------------------------

Our data indicate that polyploidization is a key event in USARC tumorigenesis except for a small outlier group of high-grade tumors without evidence of WGD as estimated by WGS (CNS3). To address this conundrum, we used ploidy cytometry analysis, which revealed that 4/6 "non-genome duplicated" CNS3 samples contained substantial cell fractions with one or more WGD events, ranging from 36% to 71% of cells in a sample ([Figures 8](#fig8){ref-type="fig"}A and 8B). This discrepancy of ploidy results between WGS and cytometry could be methodological as our WGS algorithm is blind to subclonal WGD, but it also reinforces the heterogeneous nature of these tumors as different regions from the same tumor were used for these two analyses. PD31204 contained large peaks of a relatively diploid clone (44% of cells), and sizable fractions of cells with one or two WGD events (34% and 11% of cells, respectively) ([Figure 8](#fig8){ref-type="fig"}B). These results demonstrate sequential subclonal WGD events in samples that have predominantly diploid populations of cells, which suggest that these tumors were diagnosed before the onset of a potential clonal sweep in which the WGD population of cells dominated, and that WGD and second WGD events are probably more prevalent in USARCs than our estimates using WGS of a single tumor region suggest.Figure 8Evolutionary Pathways in USARCs(A) Proportion of cells within a sample with no WGD (0×WGD), one WGD (1×WGD), or two WGDs (2×WGD) using cytometric ploidy analysis, for six samples estimated to be non-WGD through WGS.(B) Representative examples of ploidy results for CNS3 (diploid) samples. Ploidy displayed as integrated optical density (x axis) and nuclear perimeter (y axis) of each nucleus.(C) Proposed pathways of USARC tumorigenesis. Driver mutations (*TP53* and *RB1*) are early events in USARCs. Haploidization pathway: extreme anaphase mis-segregation associated with near-genome-wide haploidy, which is rescued by WGD, leading to a CNS4 pattern. Genomic loss pathway: less extreme anaphase mis-segregation generates large areas of LOH. Three signatures (CNS3, CNS2, and CNS1) that are variations of this LOH pattern but differentiated from each other by subsequent WGD. Chromothripsis pathway: anaphase mis-segregation or anaphase lagging could also lead to chromosomal micronucleation. CNS5 is a signature of this process followed by WGD. Endoreduplication pathway: a tumor cell may undergo WGD with relatively few other copy-number alterations: CNS7.

Discussion {#sec4}
==========

Through the parallel analyses of WGS, DNA methylation profiling and gene expression we have generated a comprehensive molecular and clinical landscape of USARCs. USARCs with high mutational burden (mutHi) were found to be enriched for activation of immune pathways at both the DNA methylation and gene expression levels. More effective therapeutic approaches are desperately needed for USARC patients and we propose that classifying USARCs by mutational burden is clinically relevant. Furthermore, hypermutation and the recurrence of mutations in mTOR signaling genes open up alternative avenues for stratification and immunotherapy clinical trial design for these patients.

We have illuminated the karyotypic complexity in USARCs through the development of a copy-number signature framework that has proved to be a practical method to infer evolutionary dynamics at a structural level. By integrating the results from copy-number signatures, mutational timing, and ploidy analysis we deduced four potential routes to USARC tumorigenesis, all beginning with early driver mutations, preceding any WGD event ([Figure 8](#fig8){ref-type="fig"}C). In particular, CNS4 is indicative of WGD in an inferred precursor cell that has a near-haploid chromosomal state. This genomic loss is likely achieved through a single mis-segregation event such as a mitotic error rather than through progressive loss. Live cell-imaging experiments of chromosomally unstable cells have demonstrated that mis-segregation during anaphase can lead to two aberrant daughter cells; one that is hypoploid, and another that is hyperploid due to sequestration of a lagging chromosome in a micronucleus, which may be susceptible to chromothripsis ([@bib27]). This suggests that there could be a dichotomous relationship between cells that are hypoploid (genome-wide LOH) and those in which chromothripsis can occur. Indeed, USARC samples with large-scale LOH show a negative association with signatures of chromothripsis, suggesting a different evolutionary trajectory between LOH and chromothriptic samples. Alternatively, chromothripsis may be selected against in near-haploid cells due to the potential introduction of large regions of homozygous deletions. The strong association of CNS5 with USARC.RS1, but not USARC.RS4, demonstrates that in USARC chromothripsis most often generates translocations, and suggests that there may be other signatures of chromothripsis that remain to be discovered. On a permissive background of *TP53* or *RB1* inactivation, such widespread genomic loss could lead to a precursor cell state with a near-haploid genome as seen, for example, in samples PD31196a and PD26920a. These losses likely act as a second hit in a genome-wide fashion, unmasking multiple potent pathogenic somatic or recessive germline variants simultaneously, thus dramatically increasing the fitness of an incipient cancer cell in one crisis event. Subsequent WGD through telomere-crisis-induced endoreduplication potentially increases the evolutionary space within which such a cell can optimize the dosage of various genes without risking further haploidy or loss of any survival-critical genes ([@bib12]), and, in fact, we observed gene-dosage effects dependent on copy number through our integrative analysis. Conversely there is no significant association between methylation status of driver genes and gene expression once copy number is accounted for. Furthermore, WGD dramatically accelerates tumor development leading to diagnosis soon after WGD in some cases of USARCs. In other cases, the first WGD event ranges from just before diagnosis to multiple decades before diagnosis, suggesting that other factors contribute to rapid tumorigenesis in some tumors but not in others. In contrast, a second WGD event is consistently late in the tumor\'s history, sometimes decades after the first duplication and occurring just before diagnosis. This long latency provides a clinically relevant time frame for intervention should the early driver mutations be amenable to detection in the blood circulation. Key features from the sequencing data corroborated by DNA ploidy experiments, mutational timing, and cytogenetic findings expand the view that WGD is a recurrent phenomenon in USARCs and is a potential transformation event instrumental in their development.

These new models of sarcoma development demonstrate likely punctuated evolutionary trajectories and provide insights into how patterns of LOH and copy-number gain sculpt the sarcoma genome. Future work on larger cohorts collected prospectively may elucidate other mechanisms underpinning the aberrant copy-number landscape in sarcomas and may yield further undiscovered copy-number signatures. There is also a requirement to refine these models by investigating karyotypic instability at multi-region and single-cell resolution to understand better the operative dynamics of tumor progression through copy-number evolution.

Ethics {#sec5}
======

Informed consent was obtained from all subjects and ethical approval for samples obtained from Cambridgeshire 2 Research Ethics Service (reference: 09/H0308/165). Approval to conduct the study was granted by NHS Health Research Authority (REC reference: 16/NW/0769).

STAR★Methods {#sec6}
============

Key Resources Table {#sec6.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Chemicals, Peptides, and Recombinant Proteins**MLH1 antibodyAgilent Technologiescat. NCL-L-MLH1; RRID: [AB_10555424](nif-antibody:AB_10555424){#interref185}MSH2 antibodyAgilent Technologiescat. M363901-2; RRID: [AB_2631353](nif-antibody:AB_2631353){#interref190}MSH6 antibodyAgilent Technologiescat. M364601-2PMS2 antibodyBD Biosciencescat. 556415; RRID: [AB_396410](nif-antibody:AB_396410){#interref195}ATRX antibodySigma-AldrichHPA001906; RRID: [AB_1078249](nif-antibody:AB_1078249){#interref200}Telomere FISHAgilent TechnologiesK532511-8Schiff's fuchsin-sulphite reagentSigma-AldrichS5133**Deposited data**WGS dataThis studyEGA: EGAD00001004162Methylation array dataThis studyArrayExpress: E-MTAB-6961RNA seq dataThis studyEGA: EGAD00001004439**Software and algorithms**CaVEMan([@bib54])<https://github.com/cancerit/CaVEMan>cgpPindel([@bib45])<https://github.com/cancerit/cgpPindel>BRASS([@bib41])<https://github.com/cancerit/BRASS>ASCAT NGS([@bib36])<https://github.com/cancerit/ascatNgs>Battenberg<https://github.com/cancerit/cgpBattenberg>GISTIC 2.0([@bib39])<http://portals.broadinstitute.org/cgi-bin/cancer/publications/pub_paper.cgi?mode=view&paper_id=216&p=t>Telseq([@bib14])<https://github.com/zd1/telseq>Mutational signatures([@bib2])<https://uk.mathworks.com/matlabcentral/fileexchange/38724-sigprofiler>dndSCV([@bib37])<https://github.com/im3sanger/dndscv>CIVIC database([@bib25])<https://civicdb.org/home>Genie database([@bib1])<http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx#.WyD4IjMzq34>MSKCC hotspots database([@bib11])<http://cancerhotspots.org/>Encode blacklist([@bib15])<https://www.encodeproject.org/annotations/ENCSR636HFF/>ExAC database([@bib34])<http://exac.broadinstitute.org/>Variant Effect Predictor([@bib38])<https://www.ensembl.org/info/docs/tools/vep/index.html>Recurrent rearrangementsThis paper<https://github.com/UCL-Research-Department-of-Pathology/RETREAD>Chromothripsis identificationThis paper<https://github.com/UCL-Research-Department-of-Pathology/CODER>Copy number signaturesThis paper<https://github.com/UCL-Research-Department-of-Pathology/CONUSIG>Mutation triagingThis paper<https://github.com/UCL-Research-Department-of-Pathology/Triagen>Rearrangment signatures([@bib41]), this paper<https://github.com/UCL-Research-Department-of-Pathology/RESIN>Timing whole genome doubling([@bib13])<https://github.com/galder-max/USARCtiming>HISAT2([@bib30])<https://github.com/infphilo/hisat2>Stringtie([@bib43])<https://github.com/gpertea/stringtie>Mutect2([@bib4])<https://software.broadinstitute.org/gatk/download/auth?package=GATK-archive&version=3.8-1-0-gf15c1c3ef>Lumpy([@bib33])<https://github.com/arq5x/lumpy-sv>ASCAT([@bib36])<https://github.com/Crick-CancerGenomics/ascat>

Contact for Reagent and Resource Sharing {#sec6.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to the Lead Contact, Nischalan Pillay (<n.pillay@ucl.ac.uk>).

Experimental Model and Subject Details {#sec6.3}
--------------------------------------

### Patient Samples {#sec6.3.1}

Patient tissues and data originated from the Royal National Orthopaedic Hospital biobank, pathology archives and London Sarcoma Service databases. Patient samples were obtained from the Stanmore Musculoskeletal Biobank, a satellite of the UCL/UCLH Biobank (HTA Licence Number 12055), which was approved by the National Research Ethics Committee (reference 15/YH/0311). This specific study was approved by the NHS Health Research Authority (REC reference 16/NW/0769). Informed consent was obtained from all patients.

### Case Selection {#sec6.3.2}

The pathology archives were searched for sarcomas ICD coded (<http://www.who.int/classifications/icd/en/>) as undifferentiated sarcoma, pleomorphic sarcoma or spindle cell sarcoma NOS. Only cases where both consent and frozen tissue and matching germline material were available were included. A total of 61 cases were identified where adequate nucleic acid was available. Four cases were excluded by pathology review (R.T and N.P) and immunohistochemistry profiling as they represented other sarcoma types. A further four cases were excluded on analysis of WGS results as they bore molecular hallmarks of other sarcoma types (viz. dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor and malignant solitary fibrous tumor). A total of 53 cases of undifferentiated/unclassified sarcoma were included for further study. Formalin fixed, paraffin embedded tissue blocks of the tumors that were sequenced were used for immunohistochemical and image cytometry analysis.

Method Details {#sec6.4}
--------------

### Tissue Processing and DNA Extraction {#sec6.4.1}

Tumor samples were retrieved from liquid nitrogen stores, embedded in Tissue-Tek OCT and sectioned on a cryostat. For each sample, an initial 5 μm hematoxylin and eosin (H&E) stained section was cut. Microscopic examination of tumor type and tumor cellularity was estimated by a pathologist (N.P). A minimum tumor content of 50% was required for inclusion in the study. Some cases required macrodissection to enrich for tumor content. Twenty-five sections of 20 μm thickness was then collected with a final H&E for confirmation of uniformity of tumor content.

DNA was extracted using an automated magnetic bead extraction and purification system according to the manufactures' protocols (Prepito DNA Tissue10 Kit, Perkin Elmer Ltd, Bucks,UK). DNA from blood was obtained using a column based system (Qiamp DNA Blood Maxi kit, Qiagen,Manchester,UK). DNA concentration and quality were assessed by a fluorometric assay (Picogreen, Thermofisher Scientific,Paisley,UK) and a PCR assay followed by gel electrophoresis. Only DNA that was of suitable concentration (minimum 500 ng total) and was amplifiable were used for whole genome sequencing.

### Whole-Genome Sequencing Protocol and Data Processing {#sec6.4.2}

Whole genome sequencing was performed on samples on the XTen instrument (Illumina,Chesterford,UK) according to the manufacturers protocol using 150 bp, paired-end libraries with a PCR free workflow. The average coverage of tumors was at least 70X and of normal DNA at least 30X. For classification of genome complexity there was no association between molecular subgroup and tumor purity (Kruskal Wallis test, p=0.13), suggesting that the relatively low number of mutations in the mutLo-rearrLo subgroup is not an artefact of normal tissue contamination of the tumor specimens.

### Targeted Sequencing Protocol and Data Processing {#sec6.4.3}

Genomic DNA was extracted from formalin fixed paraffin embedded tissues. Samples were chosen based on high tumor content and cellularity.

We designed a DNA target-enrichment design (SureSelect, Agilent Technologies, Santa Clara, CA, USA). We selected 350 genes implicated in cancer and/or sarcoma based on the whole genome sequencing results to serve as a validation assay, identify cancer genes not previously implicated in sarcoma and to assess the frequency of the recurrent mutations.

The bait design also incorporated an Agilent OneSeq 8 Mb copy number backbone evenly spaced across the genome and supplemented by 7000 heterozygous single nucleotide polymorphisms densely tiled across the cancer genes in the assay. DNA and library preparation was carried out as per the manufacturers protocol. Samples were sequenced on a 150 bp paired end high output NextSeq runs. Fastq files were aligned to the human genome reference build GRCh37 using BWA mem.

Hypermutation was defined with a decision boundary of 10 mutations/Mb to account for the large number of subclonal mutations; no rearrangement groups were possible to define for the extension cohort due to the nature of the assay.

### RNA Sequencing Protocol and Data Processing {#sec6.4.4}

Total RNA was isolated from frozen tissues using the Zymo Direct Zol RNA isolation kit according to manufacturers' recommendations that included the on-column DNase digestion. The quantity and quality of total RNA was assessed by NanoDrop spectrophotometer (Thermo Scientific), Qubit (Thermo Scientific) and Tapestation (Agilent). Only samples with a RIN score \>6, high quality spectrophotometer rations and RNA concentration \> 250 ng were selected for library preparation.

KAPA Stranded mRNA-Seq kit (Roche- KAPA Biosystems) was used to generate indexed Illumina platform sequencing libraries according to the manufacturer's instructions. Equimolar amounts of libraries were pooled and sequenced on an Illumina HiSeq 2500 instrument using standard protocols for paired end 100 bp sequencing with a desired sequencing depth of ∼60 million paired end reads per library.

Fastq files were aligned to the human genome build GrCh37 using HISAT2 ([@bib30]) and gene expression was quantified using stringtie ([@bib43]).

### Methylation Protocol {#sec6.4.5}

600 ng of fresh frozen DNA were bisulfite converted using the Zymo EZ DNA methylation Gold kit (Zymo Research Corp.Irvine,CA,USA) as per manufacturers recommendations. Bisulfite converted samples were processed and hybridized to the Infinium HumanMethylationEPIC beadchip arrays according to the manufacturer's recommendations.

Methylation intensities were normalized with noob background correction and functional normalization using the minfi funnorm function ([@bib3]) and converted to beta values for downstream analysis. Sex probes, SNP probes and probes with a detection p-value\>0.01 in any sample were removed from the dataset.

### Immunohistochemistry Protocol {#sec6.4.6}

All staining was performed on the Leica Bond III automated immunostaining platform, with peroxidase blocking and detection carried out using the Leica Bond Polymer Refine DAB kit (Leica, DS9800, Leica Microsystems, Milton Keynes, UK) according to manufacturer\'s instructions. Dewaxing and epitope retrieval were carried out on board using Leica Bond Dewax (Leica, AR9222) and Leica Epitope Retrieval solution 1 or 2 (Leica, AR9961, AR9640). Peroxide block (as per kit) was performed for 5 minutes at ambient temperature prior to primary antibody application. All primary antibodies were diluted in Leica Bond Primary Antibody Diluent (Leica, AR9352) and applied for 30 minutes at ambient temperature. Rabbit-anti-mouse post-primary and anti-rabbit polymer (as per kit) were sequentially applied for 20 minutes each before detection with DAB and counterstaining with hematoxylin.

#### MLH1 {#sec6.4.6.1}

MLH1 (Leica, mouse monoclonal ES05, cat. NCL-L-MLH1): diluted 1/200. Epitope retrieval: ER2 (high pH), 40 minutes, 99°C.

#### MSH2 {#sec6.4.6.2}

MSH2 (Agilent Technologies, mouse monoclonal FE11, cat. M363901-2): diluted 1/50. Epitope retrieval: ER2 (high pH), 20 minutes, 99°C.

#### MSH6 {#sec6.4.6.3}

MSH6 (Agilent Technologies, rabbit monoclonal EP49, cat. M364601-2): diluted 1/50. Epitope retrieval: ER2 (high pH), 30 minutes, 99°C.

#### PMS2 {#sec6.4.6.4}

PMS2 (BD Biosciences, mouse monoclonal A16-4, cat. 556415): diluted 1/300. Epitope retrieval: ER2 (high pH), 40 minutes, 99°C.

ATRX (Sigma-Aldrich, rabbit polyclonal HPA001906): diluted 1/500. Epitope retrieval: ER2 (high pH), 20 minutes,99°C.

### Fluorescence *In-Situ* Hybridization Protocol {#sec6.4.7}

The alternative lengthening of telomere phenomenon was investigated in the USARC cohort by telomere specific fluorescent in-situ hybridization using previously described methods. In brief, deparaffinized sections were pre-treated by pressure cooking for 5 minutes and subsequently incubated in pepsin solution at 37°C for 50 minutes. Probes (Telomere PNA FISH -- FITC; K532511-8; Agilent Technologies LDA UK Limited, Cheshire, UK) were applied to tissue sections and denatured at 72°C, and followed by hybridization overnight at 37°C. After hybridization, the sections were washed and mounted using 4′,6-diamidino-2-phenylindole with coverslips. The telomere phenotype was determined using a published method ([@bib31]). This was supplemented by assessing area of fluorescent intensity using the Olympus Cell imaging software in a minimum of 10 tumor cells per case.

### Image Cytometry Protocol {#sec6.4.8}

Based on a modified protocol of [@bib26], 50 μm FFPE sections from USARC samples were deparaffinized and rehydrated. Nuclear suspensions were obtained through cytoplasmic digestion using protease type VIII (Sigma P5380). Samples were filtered, cytospun, and subjected to DNA hydrolysis (5 M HCl) and Feulgen staining (Schiff's fuchsin-sulphite reagent; Sigma S5133). DNA ploidy was measured using the Fairfield ploidy system. A histogram with a DNA index was produced for each sample by calculating the integrated optical density.

Quantification and Statistical Analysis {#sec6.5}
---------------------------------------

### Somatic Mutation Triaging {#sec6.5.1}

Mutations were called using CaVEMan ([@bib54]) and cgpPindel ([@bib45]) for whole-genome sequencing. Only mutations that had median assembly score (ASMD)≥140 and median clipped bases (CLPM)=0 were considered reliable mutations. For targeted sequencing, mutations were called using Mutect2 from GATK v3.8 ([@bib4]). Mutations were prioritized after annotating with VEP ([@bib38]) as follows:1Variants observed in the CIVIC ([@bib25]), Sanger, Genie ([@bib1]) or Memorial Sloane Kettering Cancer Center cancer hotspots database (MSKCC) were categorized as "High confidence".2Variants overlapping the Encode Blacklist ([@bib15]), or that were unidirectional, or were seen in \>1.5% of germline reads were categorized as "Unreliable".3Silent variants were retained.4Variants observed in the ExAC database ([@bib34]) were categorized as "Unreliable".5Variants observed in \>1 patient wass categorized as "Medium confidence", otherwise "Low confidence".6"Medium confidence" variants were re-categorized as "Low confidence" if CADD score \<20, IMPACT=LOW or IMPACT=MODIFIER, while "Low confidence" variants were re-categorized as "Medium confidence" if CADD score\>20, IMPACT=HIGH or MODERATE or clinsig=pathogenic.

Potential driver mutations were those defined as "High confidence" or "Medium confidence" (see below).

### Germline Mutation Triaging {#sec6.5.2}

Germline variants were annotated using VEP. Potentially pathogenic variants were restricted to those in coding regions, including splice region variants. Variants were considered pathogenic if their clinical significance was pathogenic, their impact was high or their CADD score was ≥30. Additionally, any variant must have passed the ExAC quality filter.

### Rearrangement Triaging {#sec6.5.3}

Rearrangements were called using BRASS ([@bib41]) for whole-genome sequencing, and Lumpy for targeted sequencing. Stringent BRASS calls were defined as those that were able to be locally assembled at base pair resolution and were not observed in the germline.

Rearrangements were then classified as functional (Disruptive or Fusion), or not (Unknown significance or Benign) using BRASS fusion flags as follows:1UTR-UTR, single intron or ambiguous flags were classified as "Unknown significance".2Fusion flags with different reading frame fusion between an exon and intron, those within the same gene in different regions, those that lead to truncation, those that are a rearrangement between an intron and an intergenic region, and those that are in an opposite orientation between and intron and an exon are classified as disruptive.3Those with no predicted fusion, but which have an intronic or exonic breakpoint are classified as disruptive. Otherwise they are classified as benign.4In-frame fusions are classified as fusions.5Driver disruptions are identified as those that occur in a COSMIC TSG and are not in the UTR.6Driver fusions are categorized as those that include a COSMIC fusion gene, and the fusion partner is also included in COSMIC.

Potential driver rearrangements were identified from the functional rearrangements by cross-referencing with the COSMIC database of known cancer driver genes. Out of 452 predicted fusions involving two genes with unambiguous reading frames, 158 predicted in-frame fusions were identified in 47 samples involving 14 cancer genes (16), none of which were recurrent. Of the 14 putative fusions involving known cancer genes, none involved a known fusion partner and no recurrent novel predicted fusion genes were discovered. Moreover, further interrogation of the predicted breakpoint regions revealed that 39% of them directly overlap a known fragile site ([@bib7]).

### Copy-Number Calling {#sec6.5.4}

Allele specific copy number and ploidy were called using ASCAT NGS ([@bib36]) for whole-genome sequencing, and ASCAT for targeted sequencing. Gene level driver copy number aberrations were identified as such:

#### Amplification {#sec6.5.4.1}

Minimum total copy number across the gene \> 2^1.3^× ploidy in a known cancer amplified gene (COSMIC).

#### Homozygous Deletion {#sec6.5.4.2}

Any region within a known tumor suppressor gene (COSMIC) has allele specific copy number = {0,0}.

#### Loss of Heterozygosity {#sec6.5.4.3}

Any region within a known tumor suppressor gene (COSMIC) has allele specific copy number = {0,$\geq$1} or {$\geq$1,0}.

### Recurrent Rearrangements {#sec6.5.5}

Genomic regions containing clustered breakpoints in whole-genome sequencing were found by binning the human genome into 1 Mb bins and counting the number of samples with \>1 rearrangement breakpoint as identified by stringent BRASS calls (described above) in each ([@bib42]). To determine a suitable threshold above which to call recurrence significant, 10,000 Monte Carlo simulations of random breakpoint partners were performed as follows:

Let *p* be the probability of breakpoint partners being on the same chromosome (determined empirically from the dataset). Then:$$n \sim 1 + Bin\left( {1 - p} \right)\text{,}$$where *n* is the number of chromosomes involved in the rearrangement.

Let *s*~*c*~ be the start position of the *c*th chromosome from set ***C***={1,2,...,*X*,*Y*}, and *e*~*c*~ be the end position.

Then draw *n* chromosomes from ***C*** with probability. ${\left\{ {e_{1} - s_{1},e_{2} - s_{2},\ldots,e_{X} - s_{X},e_{Y} - s_{Y}} \right\}/{\sum\limits_{i \in \mathbf{C}}{e_{i} - s_{i}}}}\text{.}$

If *n*=2, then:$$B_{c} \sim U\left( {s_{c},e_{c}} \right)\text{,}$$where *B*~*c*~ are the breakpoints drawn from the *c*th chromosomes.

If instead *n*=1, then:$$D \sim Exp\left( {1/\mu_{c}} \right)\text{,}$$where *D* is the distance between the two breakpoints, and *μ*~*c*~ is the mean distance between breakpoints on the *c*th chromosome (determined empirically from the dataset). Then:$$B_{1,c} \sim U\left( {s_{c},e_{c} - D} \right)\text{,}$$and:$$B_{2,c} = B_{1,c} + D\text{,}$$where *B*~1,*c*~ and *B*~2,*c*~ are the 1^st^ and 2^nd^ breakpoint on chromosome *c*.

If, ***O*** is the set of number of rearrangements observed in all samples in the dataset, then rearrangements are simulated *N* times as:$$N \sim Gamma\left. \left( {\mathbf{k},\mathbf{\theta}} \right) \right)\text{.}$$where $k$ and *θ* are the shape and scale parameters of the gamma distribution, which are estimated from ***O*** by maximum likelihood (fitdistr, R MASS package). For each Monte Carlo simulation, *x* simulated samples are generated, where *x* matched the number of samples in the dataset.

For a genomic bin with *i* observed samples with breakpoints, the p-value is then (*m*+1)/(*M*+1), where *m* is the number of simulations with observed samples \>*i*, and *M* is the number of simulations, here 10,000 . Q-values are then calculated as:$$q_{i} = \underset{i \leq j \leq M}{\text{min}}\frac{M\pi_{0}P_{j}}{j}$$where:$$\pi_{0} = \text{min}\left( {1,\frac{2}{M}\sum\limits_{i = 1}^{M}P} \right)_{i}\text{,}$$where P are the ordered p-values. Any Q-value \<0.2 was considered significant.

### Recurrent Copy Number Alterations {#sec6.5.6}

Recurrent copy number alterations from whole-genome sequencing at a gene level (-genegistic) were identified using GISTIC 2.0 ([@bib39]) with a broad analysis (-broad) and arm level peel off (-armpeel), a threshold for deletions and amplifications of 0.25 (-ta,-td), a threshold for broad events of 0.98 (-brlen). The confidence level for calculating driver regions was 0.90 (-conf). Marker-level copy number data was collapsed to gene-level data using the extreme method (-gcm).

### Chromothripsis Identification {#sec6.5.7}

Regions of chromothripsis were identified using criteria outlined in [@bib32], namely through clustering of breakpoints, randomness of DNA fragment joins and randomness of DNA fragment order. Chromothripsis was interrogated in sliding windows of 3 Mb, with a spacing of 100 kb. Only chromosomes with \>30 breakpoints were considered. A Kolgomorov-Smirnov test was performed on distances between breakpoints of a whole chromosome (not a sliding window) against the exponential distribution with mean equal to the mean breakpoint distance, a p-value threshold \<0.05 was used as [@bib32] state chromothriptic chromosomes have a strong departure from a random distribution. A goodness of fit test was performed on the counts of {HH, HT, TH, TT} joins with a null distribution of {0.25, 0.25, 0.25, 0.25} to test for random DNA joins in sliding windows. A monte carlo simulation of 1000 draws of two breakpoints was performed on sliding windows to test random order, where the p-value was the proportion of simulations where $\left| {i_{1,s} - i_{2,s}} \right| > \overline{\left| {i_{1,d}-i_{2,d}} \right|}$ where *i*~1,*s*~ is the ordered index of the first breakpoint in the simulated pair of breakpoints, and *i*~1,*d*~ is the ordered index of the first breakpoint of a rearrangement pair in the dataset. For random joins and random order a looser threshold of p\>0.8 was used, as these tests are aiming to accept the null rather than reject it, and in particular [@bib32] state that the random order of breakpoints is not entirely random, but more random than a scenario of independent structural rearrangement. If two of the three tests indicated chromothripsis, the window was designated as a potentially chromothriptic event. Note that these tests are able to identify events that do not behave like classical chromothripsis (oscillating between two copy number states, one of which is LOH), but share the hallmarks of chromothripsis. A strict definition of two copy number states was not employed as it precludes copy number alteration preceding or subsequent to chromothripsis, and chromothripsis events have previously been described that involve ≫2 copy number states ([@bib5], [@bib21], [@bib49]). Likewise, a strict definition requiring oscillating between LOH and non-LOH segments was not incorporated, as it precludes chromothripsis after a WGD event, which is prevalent in our dataset.

Overlapping windows of potentially chromothriptic events were merged. All chromothripsis calls were manually reviewed.

Similar to above, recurrent chromothripsis events were identified by binning the genome into 100 kb bins and counting the number of samples that had a chromothripsis event overlapping each bin.

### Telomere Length Estimation {#sec6.5.8}

Telomere lengths were estimated from whole genome sequencing reads with a published tool Telseq and using the authors recommended settings ([@bib14]). The weighted average of reads containing at least 7 instances of the telomeric motif TTAGGG in a read group was used to estimate the length.

### Mutational Signatures {#sec6.5.9}

Mutational signatures were identified using non-negative matrix factorization (NMF) of counts of the triplet context of each mutation in each sample ([@bib2]).

### Rearrangement Signatures {#sec6.5.10}

Rearrangement signatures were identified using NMF of counts of rearrangements in each sample, classified by type (insertion, deletion, tandem-duplication, translocation), size (1-10 kb, 10 kb-100 kb, 100 kb-1 Mb, 1 Mb-10 Mb, \>10 Mb) and whether the rearrangement was clustered or unclustered. The method for determining clustered or unclustered rearrangements was altered from [@bib41]; we determine clustered rearrangements as those falling in a piecewise constant fit segment with an average distance between rearrangements less than 0.1x the mean distance between rearrangements across the data set, rather than 0.1x the mean distance between rearrangements in a given sample as is the case in [@bib41]. This avoids samples with a majority of rearrangements arising from chromothripsis having none of them called as clustered.

### Copy Number Signatures {#sec6.5.11}

Copy number signatures were identified from ASCAT allele-specific copy number profiles using NMF. Copy number segments were classified as heterozygous, LOH or homozygous deletions. These were further subclassified by total copy number (0-1=deleted, 2=neutral, 3-4=duplicated, \>4=amplified). These were then further subclassified by size of segment (0-0.01 Mb, 0.01-0.1 Mb, 0.1-1 Mb, 1-10 Mb, \>10 Mb). This gives a total of 40 mutually exclusive categories a segment can be classified as; 20 LOH categories, 15 heterozygous categories and 5 homozygous deletion categories. NMF was run with ranks 2 through 12 for 1000 runs. The appropriate rank was selected to maximize the consensus silhouette width, the cophenetic distance and the dispersion of clusters. NMF was also run for 1000 runs with ranks 2 through 12 on a randomized version of the data to avoid overfitting.

Following NMF, the deconstructSigs R package ([@bib47]) was used to estimate the exposure of each identified signature in each sample, to reduce overfitting of the exposures to the data.

### Validation Cohort {#sec6.5.12}

A validation cohort of copy number profiles called by ASCAT were collated from published datasets: 43 chondrosarcoma SNP arrays ([@bib51]), 112 osteosarcoma SNP arrays ([@bib5]) and 203 mixed soft tissue sarcoma SNP arrays ([@bib52]). To these we added 15 low grade and assorted sarcoma whole genomes.

Copy number signatures were identified in this cohort in the same manner as for the USARC cohort. Cosine similarities between the USARC signatures and validation signatures were used to determine if signatures were shared across the two cohorts.

Additionally, the validation cohort was scanned for the original USARC copy number signatures using the deconstructSigs R package.

The diversity of copy number signatures identified in each sample for both the validation cohort and the USARC cohort was quantified using Shannon's diversity index as:$$H = - \sum\limits_{i = 1}^{n}{p_{i}\ \ln\ p_{i}}\text{,}$$where *n* is the number of signatures identified in the sample with exposure \>0 and *p*~*i*~ is the normalized exposure of the *i*th signature with exposure \>0. Exposures of signatures were normalized to sum to 1.

The probability of the large-scale LOH occurring before WGD is higher than LOH after WGD (P=0.63 and 0.22 respectively, assuming independent chromosome segregation over all possibilities of chromosome segregation events in a model given a diploid or tetraploid cell state).

### Survival Analysis {#sec6.5.13}

Associations with survival were identified using an accelerated failure time (AFT) model. This model was used because the Cox proportional hazards model's assumption of proportional hazards is violated by several key covariates: resection margins, metastasis status, RB1 mutation status and ATRX mutation status. Patients with only non-primary tumor samples were excluded from analysis. Genetic covariates for a patient with both a primary and metastasis sample were based on the primary sample only. A log-normal AFT model was fit to the log survival times of patients.

An AFT model for overall survival was fit with covariates: size of tumor (mm), resection margins (Complete, Marginal, Incomplete), metastasis status (Metastasis at diagnosis, Metastasis after diagnosis, No metastasis, Unknown) and burden group (mutLo-rearrLo, mutLo-rearrHi, mutHi-rearrLo).

AFT models for metastasis-free survival and progression-free survival were fit with covariates: size of tumor (mm), resection margins (Complete, Marginal, Incomplete) and burden group (mutLo-rearrLo, mutLo-rearrHi, mutHi-rearrLo).

Other models were fit with genetic mutations of *TP53*, *ATRX*, *RB1*, *CDKN2A* and *PTEN* as extra covariates, but none of these were significant. Additional clinical covariates that were previously modelled but found to be non-significant were age at diagnosis, gender, recurrence status. Additional genetic covariates that were previously modelled but found to be non-significant were rearrangement signatures and copy number signatures.

### Timing of Whole Genome Duplications {#sec6.5.14}

To time whole genome duplications we first inferred the multiplicity of each single nucleotide variant (SNV), i.e. the number of bearing alleles of the mutation ([@bib13]). Briefly, the most likely multiplicity of an SNV *μ*~*SNV*~, given the purity of the sample *ρ*, the underlying total tumor copy number *n*~*tot,t,SNV*~ and the variant allele fraction of the SNV *f*~*SNV*~ is the integer bound by the underlying major allele state of the tumor *n*~*major\ ,t,SNV*~, inferred as:$$\left\langle {{{argmin}_{\mu}}_{SNV}\left( \left| {f_{SNV}\frac{1}{\rho\mu_{SNV}}\left( {\rho n_{tot,t,SNV} + \left( {1 - \rho} \right)n_{tot,n,SNV}} \right) - 1} \right| \right)\left| {\mu_{SNV} \in N_{0}\text{,}\ \mu_{SNV} \leq n_{major,t,\mathit{SNV}}} \right.} \right\rangle\ $$where n~tot,n,SNV~=2 is the total copy number of the normal diploid contaminant. As a second step, we separately time whole genome duplications (WGD) in samples having undergone a single WGD (WGDx1) and two WGDs (WGDx2):1)WGDx1: in regions of the genome represented by 2 copies of the major allele and 0 or 2 copies of the minor allele (annotated 2+0 and 2+2), we count the number of SNVs with a multiplicity of 2 *N2*, i.e. acquired prior to the WGD and the SNVs with a multiplicity of 1 *N1*, i.e. acquired posterior to the WGD. We then time the WGD in relative mutational timing t~WGD1~:$$t_{WGD1_{2 + 0,2 + 2}} = \frac{N2}{\frac{N1}{2} + N2}$$2)WGDx2: similarly to WGDx1, in regions of the genome represented by 4 copies of the major allele and 0 or 4 copies of the minor allele (annotated 4+0 and 4+4) we count the number of SNVs with a multiplicity of 4 *N4*, i.e. acquired prior to the first WGD, a multiplicity of 2 *N2*, i.e. acquired prior to the second WGD but posterior to the first, and a multiplicity of 1 *N1*, i.e. late SNVs. We then time the first and second WGDs in relative mutational timing t~WGD1~ and t~WGD2~, resp.:$$t_{WGD1_{4 + 0,4 + 4}} = \frac{N4}{N4 + \frac{N2}{2} + \frac{N1}{4}}$$$$t_{WGD2_{4 + 0,4 + 4}} = \frac{N4 + \frac{N2}{2}}{N4 + \frac{N2}{2} + \frac{N1}{4}}$$

We compute the 95% confidence intervals from 1,000 bootstrapping of the multiplicities.

Finally, using the same rationale, i.e. early mutations in duplicated regions appear on all duplicated copies, we infer timing of drivers relative to the WGDs from their estimated multiplicities, if they fall in 2+2 or 2+0 regions, and 4+0 or 4+4 regions for WGDx1 and WGDx2, respectively.

To time WGD in TCGA data, we applied the same concepts as outlined, however, we first selected only samples with a major allele ≥2 ([Figure S7](#mmc1){ref-type="supplementary-material"}A), i.e. with at least one WGD, and for which our ploidy estimates matched the ploidy estimates in the TCGA publication ([@bib52]) ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Timing of WGD events further allowed for testing the possibility of an artefactual origin of the mutLo-rearrLo molecular class. There was no association between either ploidy status or WGD timing with molecular class (Kruskal-Wallis test, p\>0.05). Additionally, there was no significant association between WGD timing, ploidy or normal contamination with rearrangement count in a multivariate regression, as well as no significant interaction between any of the three variables (all p\>0.05).

### Real-Time Timing {#sec6.5.15}

Following the rationale in [@bib23], we scale the relative mutational timing from 0 to the age at diagnosis of the patients. As the acceleration rates are unknown, we did not simulate any acceleration rates. Therefore, our timing estimates might be later than if accounting for acceleration of the clock. So, for a given relative timing of e.g. a whole genome duplication *t*~*WGD1*~ in a patient whose age at diagnosis was *a*, the real-time timing of the WGD *rt*~*WGD1*~ becomes$$rt_{WGD1} = a \times t_{WGD1}$$and the WGD occurred *tbd*~*WGD1*~ years before diagnosis$$tbd_{WGD1} = a - rt_{WGD1}$$

We verified that the number of spontaneous (C\>T)pG were correlated with the age at diagnosis ([Figure S7](#mmc1){ref-type="supplementary-material"}C), as well as strongly correlated with the total number of mutations *N*~*SNV*~ ([Figure S7](#mmc1){ref-type="supplementary-material"}D), and *N*~*SNV*~ were therefore also correlated with the age of the patients ([Figure S7](#mmc1){ref-type="supplementary-material"}E). Not to lose too many mutations for the real-time estimates of WGD, we used all mutations to derive the relative timing and real-time timing. In our USARC cohort, we verified that the results using only (C\>T)pG, where the numbers were sufficient yielded very similar estimates and overall picture ([Figure S7](#mmc1){ref-type="supplementary-material"}F). Using all mutations, we could time WGD in the TCGA exome data, in which the number of mutations is limited and timing using only (C\>T)pG becomes inaccurate or even unfeasible.

### Gene Set Enrichment Analysis (GSEA) {#sec6.5.16}

We performed GSEA using MSigDB collections ([@bib50]): c2 KEGG, c2 REACTOME, c5 CC, c5 MF, c6 ALL. To run GSEA, one summary value per gene symbol was used. For each gene, we collapsed the matrix of log2 TPM expression values and the matrix of beta methylation values to the most variable entry. We then selected the 20,000 most variable genes across all samples. We ran two-class GSEA using the signal-to-noise metric with 200 permutations and looked into gene sets with q-value\<0.1 (slightly stricter than GSEA recommendation q-value\<0.25).

### Linear Modelling of Gene Expression {#sec6.5.17}

Linear models of gene expression against independent variables were explored for *TP53*, *RB1*, *CDKN2A*, *ATRX*, *PTEN*, *MEN1*, *TERT*, *MSH6*, *MSH2* and *MBD4*. Initial models were parameterized as:$$\gamma = \beta_{0} + \beta_{1}\pi + \beta_{2}\chi\text{,}$$where *γ* is gene expression, *π* is tumor purity and *χ* is minimum gene copy number. These models were further expanded to include methylation probe beta values, $\mu$, as dependent variables:$$\gamma = \beta_{0} + \beta_{1}\pi + \beta_{2}\chi + \beta_{3}\mu\text{.}$$

The p-values for copy number from the initial models were corrected for multiple testing over 10 genes, while the p-values for methylation probe beta values were corrected for multiple testing over 402 probes.

### Statistical Analysis {#sec6.5.18}

All statistical analysis was performed using R ([@bib44]). Survival analysis was performed using the survival ([@bib53]) and flexsurv ([@bib28]) packages. NMF was performed using the NMF ([@bib22]) package.

Data and Software Availability {#sec6.6}
------------------------------

### Software Availability {#sec6.6.1}

Our implementations of methods are available at:

<https://github.com/UCL-Research-Department-of-Pathology>.

<https://uk.mathworks.com/matlabcentral/fileexchange/38724-sigprofiler>.

<https://github.com/galder-max/USARCtiming>.

### Data Availability {#sec6.6.2}

The accession number for the whole genome sequencing reported in this paper is deposited in EGA database at EMBL-EBI (<https://www.ebi.ac.uk/ega/about/access>) under accession number EGAD00001004162.

The accession number for the methylation array data reported in this paper is deposited in the ArrayExpress database at EMBL-EBI ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress){#intref0170}) under accession number E-MTAB-6961.

The accession number for the RNA sequencing data reported in this paper is deposited in EGA database under accession number EGAD00001004439.
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